These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24844045)

  • 21. Free Speech and Pharmaceutical Regulation -- Fishy Business.
    Kapczynski A
    JAMA Intern Med; 2016 Mar; 176(3):295-6. PubMed ID: 26832191
    [No Abstract]   [Full Text] [Related]  

  • 22. Over-the-counter sales of statins and other drugs for asymptomatic conditions.
    Tinetti ME
    N Engl J Med; 2008 Jun; 358(25):2728-32. PubMed ID: 18565867
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 25. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB; Yentzer BA; Feldman SR
    Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Certification denied in pharmaceutical class action.
    Boudreau A; Tombs A
    Health Law Can; 2012 Aug; 33(1):1-4. PubMed ID: 23097924
    [No Abstract]   [Full Text] [Related]  

  • 27. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 28. The commercial speech doctrine in health regulation: the clash between the public interest in a robust First Amendment and the public interest in effective protection from harm.
    Orentlicher D
    Am J Law Med; 2011; 37(2-3):299-314. PubMed ID: 21847883
    [No Abstract]   [Full Text] [Related]  

  • 29. Caveat doctor.
    McCarthy M
    Lancet; 1999 Aug; 354(9177):446. PubMed ID: 10465167
    [No Abstract]   [Full Text] [Related]  

  • 30. Bitter pills for drug companies.
    Newman M
    BMJ; 2010 Sep; 341():c5095. PubMed ID: 20851842
    [No Abstract]   [Full Text] [Related]  

  • 31. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

  • 32. Company pays over $81m for allegedly promoting topiramate for unapproved uses.
    Kmietowicz Z
    BMJ; 2010 May; 340():c2848. PubMed ID: 20508021
    [No Abstract]   [Full Text] [Related]  

  • 33. The limits of free speech.
    Nature; 2012 Dec; 492(7429):311. PubMed ID: 23281497
    [No Abstract]   [Full Text] [Related]  

  • 34. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 35. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 37. A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report.
    Chen B; Restaino J; Norris L; Xirasagar S; Qureshi ZP; McKoy JM; Lopez IS; Trenery A; Murday A; Kahn A; Mattison DR; Ray P; Sartor O; Bennett CL
    J Oncol Pract; 2012 Nov; 8(6):e158-67. PubMed ID: 23598851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The strange allure of state "right-to-try" laws.
    Zettler PJ; Greely HT
    JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
    [No Abstract]   [Full Text] [Related]  

  • 39. Major issues in marketing regulation.
    Pines WL
    Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
    [No Abstract]   [Full Text] [Related]  

  • 40. The pharmaceutical industry and disease mongering. Will industry's latest moves promote public health or private profit?
    McKechnie S
    BMJ; 2002 Jul; 325(7357):216; author reply 216. PubMed ID: 12143862
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.